Drug Trial Radar · NCT07735104
The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Oct 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia
Conditions
- Cancer Cachexia
- Cancer Cachexia Syndrome
Interventions
QLS2319Drug
QLS2319 will be administered via subcutaneous injection
PlaceboDrug
placebo will be administered via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia:Safety and tolerability after a single subcutaneous injection of QLS2319/placeboTime frame: Up to Day 99
- Phase Ib:Safety and tolerability after multiple subcutaneous injections of QLS2319Time frame: Up to 12 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Sun-Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.